Navigation Links
CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007

illed with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response in order to suppress an "allergic" Th2 type immune response. An earlier, open-label phase IIa study with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose showed excellent long-term efficacy in patients allergic to dust mites. Furthermore, two placebo-controlled phase IIa studies with CYT003-QbG10 delivered positive results in patients suffering from allergic rhinitis due to grass pollen allergy and house dust mite allergy. CYT003-QbG10 is currently being studied in clinical trials for the treatment of allergic rhinitis and atopic dermatitis.

Please feel free to contact us at the address below should you wish to receive further information, address questions, or arrange meetings with Cytos Biotechnology directly.

With best regards,

Claudine Blaser

For more information please contact:

Claudine Blaser, PhD Director Corporate Communications Cytos Biotechnology AG Wagistrasse 25, Postfach CH-8952 Schlieren (Zurich) Tel. +41 44 733 47 20 Fax. +41 44 733 47 18 e-mail: claudine.blaser@cytos.com www.cytos.com


'"/>




Page: 1 2

Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
5. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
6. Basilea Reports Positive Re-treatment Results from a Second Phase III Trial of Alitretinoin for Patients with Severe Chronic Hand Eczema
7. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
8. Data to be presented at AAN Meeting -Study results of drug candidate for MS
9. Data supporting three Antisoma programmes presented at AACR
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis

Post Your Comments:
(Date:11/6/2009)...SEARCH TRIANGLE PARK, N.C., Nov. 6 ...cing orally-available antiviral therapeutics to ad... on the development of the company,s lead antivira...on (WHO) and the Global Health Security Initiative...nt being developed for the treatment of smallpox, ...
(Date:11/6/2009)...TROIT, Nov. 6 Caraco Pha...has launched ketorolac tromethamine ophthalmic sol... Food and Drug Administration (FDA) for Sun Pharma...eric Acular® opthalmic solution on the first ...ketorolac is therapeutically equivalent to Acular&...
(Date:11/5/2009)...N DIEGO, Nov. 5 Althea Technologi...nufacturing services for biopharmaceutical product... Development to the company,s platform of services.... James Matsuura, Director of Formulation Developm...mulation and analytical scientists, along with new...
Breaking Medicine Technology:Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution 2Althea Technologies Adds Formulation Development to Its Integrated Offering of Contract Services 2Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 1Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 2Commonwealth Fund Case Study Points to Continuous Innovation at Group Health Cooperative 4643 3National Day of Health Care Service 49961 1Tyco Electronics Appoints Cuong Do as Senior Vice President Corporate Strategy 26 Business Development 49958 1Tyco Electronics Appoints Cuong Do as Senior Vice President Corporate Strategy 26 Business Development 49958 2
...SAN MATEO, Calif., Oct. 3 Anthera Pharmaceuticals...developing,anti-inflammatory therapeutics for chro...y the completion of enrollment and patient dosing ...d, A-002 for stable coronary,artery disease. Data ...f,the year. "We are pleased with the rapid enroll...
...NEW YORK, Oct. 2 ImClone Systems Incorporated,(Na...SE: BMY ) today announced,that the U.S. Food and ...o,the ERBITUX(R) (Cetuximab) product labeling to i...epidermal growth factor inhibitor,(EGFR)-expressin...er,failure of both irinotecan- and oxaliplatin-bas...
Other Medicine Technology:Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 2Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
(Date:11/8/2009)... UCW Academy of Health holds open ... Victoria, BC (Vocus) November 8, 2009 -- UCW Aca...areer in British Columbia’s health care indu...nesday, November 25, 2009. , ,UCW Academy of Heal...tration, nursing and social services, designs its ...
(Date:11/8/2009)...HINGTON, Nov. 8 Speaker...conference following the House passage of H.R. 396...e bill passed by a vote of 220 to 215. Below are ...of my colleagues just received a call from the Pre...ulating us on a great victory for the American peo...
(Date:11/8/2009)... 3D Global Solutions is pleased to...anaging the proposal effort for ReSound who recent...l Hearing Aid contract. The award includes not onl...ment of Defense and other federal agencies. , ... 8, 2009 -- 3D Global Solutions is pleased to anno...
(Date:11/8/2009)... A jury of 8 people in the Western...oman $2,300,000 in pain and suffering for a medica...es Tallman and Alicia Nocera of Thomas E. Crenney ...the plaintiff, Vita Monestersky and against the Un...ncy total abdominal hysterectomy at age 18. , ...
(Date:11/8/2009)...tion,s largest network of Hispanic health advocate...form in 2009 ,, WASHINGTON, Nov. 7 /PRNewswire...ntatives showed they have heard the voice of Ameri...e for America Act. Now the Senate must deliver, wi...are reform," said Dr. Jane L. Delgado, President a...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2
...bine Online Education with On-Site Clinical Prepar...IANAPOLIS, March 10 In response to a growing shor...day Marian College and St.Vincent Health announc...e first of its kind in Indiana to incorporate lead...
...rch 10 A diverse coalition of clergy and lay memb...a press conference today to call on U.S. Senators ...Iowa congressional delegation to support legislati... last session of Congress, Senator Grassley was no...
...J., March 10 The Institute for Patient Blood Mana...y the NJ Institute for Bloodless Medicine and Surg...brates its 15th anniversary this year. The new nam...1994 inception of the Institute, Englewood Hospita...
...body weight and sustained it for 6 months, study f...) -- A 12-week church-based weight loss program he...r more of their body weight, and most of them main...They took part in a pilot program conducted by lay...
...arch 10 Representatives Gene Green (D-TX), Ed Whi...Diana DeGette (D-CO), Mike Rogers (R-MI), Betty Su...and Ralph Hall (R-TX) today introduced H.R. 1392. ... the Medicare Program by excluding customary promp...
...mpuCyte Corporation and the Program in Cellular an... (also known as the Immune Disease Institute) toda...ive Imaging Cytometry program. The Program in Cel...reement, CompuCyte will make its proprietary laser...
Other Medicine News:Health News:Marian College and St.Vincent Health Announce Collaboration To Address Nursing Shortage in Indiana 2Health News:Marian College and St.Vincent Health Announce Collaboration To Address Nursing Shortage in Indiana 3Health News:Faith Leaders Call on Iowa Members of Congress to Support Legislation to Protect Kids from Tobacco 2Health News:Faith Leaders Call on Iowa Members of Congress to Support Legislation to Protect Kids from Tobacco 3Health News:Englewood Hospital Marks 15 Years of Leadership in Improving Patient Outcomes Through Bloodless Medicine and Surgery 2Health News:Englewood Hospital Marks 15 Years of Leadership in Improving Patient Outcomes Through Bloodless Medicine and Surgery 3Health News:Church-Based Weight Plan Peels Off Pounds for Blacks 2Health News:House Bill to Improve Accuracy of Medicare Reimbursement Introduced: Members of Congress Seek to Stem Growing Healthcare Coverage Shortfalls, Community Oncology Alliance Advocates for Swift Passage of Bill 2Health News:House Bill to Improve Accuracy of Medicare Reimbursement Introduced: Members of Congress Seek to Stem Growing Healthcare Coverage Shortfalls, Community Oncology Alliance Advocates for Swift Passage of Bill 3Health News:CompuCyte Corporation and Program in Cellular and Molecular Medicine at Children's Hospital Boston Announce Joint Program for Quantitative Imaging Cytometry Research Services 2
...Quant Rapid Opiate II Rapid Opiates is an immunoch...esigned for qualitative determination of Opiates a...esence of morphine in human urine above a cut-off ...s not been evaluated in the point of care,location...
Methadone - Rapid Test
Amphetamine - Rapid Test
... Applied Biosystems introduced the completely auto...yzer.,Now the innovative technology of the 3100 ...ABI PRISM 3100-Avant Genetic,Analyzer. Designed ...e fully automated 3100-Avant system can analyze,...
Medicine Products: